orantinib has been researched along with pd 173074 in 1 studies
| Studies (orantinib) | Trials (orantinib) | Recent Studies (post-2010) (orantinib) | Studies (pd 173074) | Trials (pd 173074) | Recent Studies (post-2010) (pd 173074) |
|---|---|---|---|---|---|
| 110 | 19 | 36 | 160 | 0 | 106 |
| Protein | Taxonomy | orantinib (IC50) | pd 173074 (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Mus musculus (house mouse) | 0.028 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.0217 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.028 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.19 | |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | 0.013 | |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | 0.5337 | |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | 0.0268 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.19 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1325 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonyarat, C; Grierson, DS; Kammasud, N; Saiki, I; Sakurai, H; Tsunoda, S; Vajragupta, O | 1 |
1 other study(ies) available for orantinib and pd 173074
| Article | Year |
|---|---|
Novel inhibitor for fibroblast growth factor receptor tyrosine kinase.
Topics: Chemistry, Pharmaceutical; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Fibroblast Growth Factor 1; Humans; Hydrogen Bonding; Indoles; JNK Mitogen-Activated Protein Kinases; Lysine; Models, Chemical; Molecular Conformation; Oxindoles; Propionates; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1 | 2007 |